Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $3.06
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
Daily · Wilder smoothing
| Jun 1, 26 |
| Evercore ISI Group |
| maintain |
| Outperform |
| Outperform |
| Feb 27, 26 | Barclays | maintain | Overweight | Overweight |
| Feb 23, 26 | Brookline Capital | maintain | Buy | Buy |
| Dec 17, 25 | Barclays | maintain | Overweight | Overweight |
| Sep 23, 25 | Wells Fargo | maintain | Overweight | Overweight |
| Sep 23, 25 | Barclays | maintain | Overweight | Overweight |
| Sep 22, 25 | Stephens & Co. | maintain | Overweight | Overweight |
| Sep 15, 25 | Stephens & Co. | upgrade | Equal Weight | Overweight |
| Dec 19, 24 | Wells Fargo | upgrade | Equal Weight | Overweight |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 48.45 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 75.89 | Oscillator | Neutral |
| Williams %R (14) | -33.80 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.08 (Hist 0.06) | Oscillator | Buy |
| Average Directional Index (14) | 17.72 (+DI 25.9 / -DI 25.7) | Trend | Neutral |
| EMA 20 | 3.05 | MA | Buy |
| SMA 20 | 2.99 | MA | Buy |
| EMA 50 | 3.27 | MA | Strong Sell |
| SMA 50 | 3.42 | MA | Strong Sell |
| SMA 200 | 3.18 | MA | Strong Sell |
Stock news · updated daily
Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings. Profitability This table compares Tenaya Therapeutics and
—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J., Oct. 20, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Paul Hudson and Utpal Koppikar as independent members of its Board of Directors, effective immediately.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -0.23 | -0.18 | Beat 20.5% | $6.64M |
| May 12, 2026 | -0.25 | -0.20 | Beat 20.2% | $6.20M |
| Feb 26, 2026 | -0.31 | -0.18 | Beat 41.9% | $11.02M |
| Nov 6, 2025 | -0.41 | -0.44 | Miss -8.5% | $11.20M |
| Aug 7, 2025 | -0.38 | -0.37 | Beat 2.6% | $6.46M |
| May 6, 2025 | -0.48 | -0.37 | Beat 22.9% | $7.20M |
TTM vs. 5-year historical average (annual ratios)
| Metric | CCCC | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -3.1x | -5.2x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -3.6x | EPS est. -0.85 | Elevated |
| Price / Book | 1.6x | 1.5x | In line |
| Price / Sales | 10.7x | 13.3x | Discount |
| EV / EBITDA | -3.6x | -5.3x | Discount |
| Return on equity | -45.5% | — | Weak |
| Gross margin | 94.9% | 88.1% | In line |
| Debt / Equity | 0.23 | 0.25 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -1.17 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 2, 2026 | 2026-10-02 16:43:49 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:43:42 | View |
| 8-K | Sep 25, 2026 | 2026-09-25 07:04:25 | View |
| 4 | Sep 21, 2026 | 2026-09-21 16:24:49 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 16:40:21 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 16:32:15 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 12:54:25 | View |
| SC 13G/A | Aug 12, 2026 | 2026-08-12 16:41:54 | View |
| 10-Q | Aug 11, 2026 | 2026-08-11 07:29:11 | View |
| 8-K | Aug 11, 2026 | 2026-08-11 07:14:05 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Anderson Kenneth Carl | director | A-Award | 3,662 @ $3.14 | $11.50K |
| Oct 1, 26 | Grogan Donna Roy | director | A-Award | 4,618 @ $3.14 | $14.50K |
| Sep 18, 26 | Adams Kendra | officer: Chief Financial Officer | M-Exempt | 6,250 | — |
| Sep 18, 26 | Adams Kendra | officer: Chief Financial Officer | F-InKind | 2,775 @ $3.39 | $9.41K |
| Jul 10, 26 | Reyno Leonard | officer: Chief Medical Officer | M-Exempt | 15,325 | — |
| Jul 10, 26 | Reyno Leonard | officer: Chief Medical Officer | F-InKind | 7,397 @ $4.06 | $30.03K |
| Jul 1, 26 | Anderson Kenneth Carl | director | A-Award | 2,650 @ $4.34 | $11.50K |
| Jul 1, 26 | Grogan Donna Roy | director | A-Award | 3,341 @ $4.34 | $14.50K |